Abstract
An 81-year-old woman developed symptomatic liver disease 3 weeks after beginning clopidogrel as adjunctive antiplatelet therapy for a coronary stent implantation. Symptomatic liver disease associated with short-term periprocedural administration of clopidogrel for coronary stenting has not been well described. The clinical significance of this event as well as a possible interaction between clopidogrel and other drugs metabolized by the cytochrome P450 2C9 pathways coadministered to this patient are discussed.
| Original language | English |
|---|---|
| Pages (from-to) | 317-318 |
| Number of pages | 2 |
| Journal | American Journal of Therapeutics |
| Volume | 7 |
| Issue number | 5 |
| State | Published - Dec 1 2000 |
| Externally published | Yes |
Fingerprint
Keywords
- Clopidogrel
- Drug-induced hepatotoxicity
ASJC Scopus subject areas
- Pharmacology
Cite this
Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. / Willens, Howard J.
In: American Journal of Therapeutics, Vol. 7, No. 5, 01.12.2000, p. 317-318.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clopidogrel-induced mixed hepatocellular and cholestatic liver injury
AU - Willens, Howard J.
PY - 2000/12/1
Y1 - 2000/12/1
N2 - An 81-year-old woman developed symptomatic liver disease 3 weeks after beginning clopidogrel as adjunctive antiplatelet therapy for a coronary stent implantation. Symptomatic liver disease associated with short-term periprocedural administration of clopidogrel for coronary stenting has not been well described. The clinical significance of this event as well as a possible interaction between clopidogrel and other drugs metabolized by the cytochrome P450 2C9 pathways coadministered to this patient are discussed.
AB - An 81-year-old woman developed symptomatic liver disease 3 weeks after beginning clopidogrel as adjunctive antiplatelet therapy for a coronary stent implantation. Symptomatic liver disease associated with short-term periprocedural administration of clopidogrel for coronary stenting has not been well described. The clinical significance of this event as well as a possible interaction between clopidogrel and other drugs metabolized by the cytochrome P450 2C9 pathways coadministered to this patient are discussed.
KW - Clopidogrel
KW - Drug-induced hepatotoxicity
UR - http://www.scopus.com/inward/record.url?scp=0034278708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0034278708&partnerID=8YFLogxK
M3 - Article
C2 - 11317178
AN - SCOPUS:0034278708
VL - 7
SP - 317
EP - 318
JO - American Journal of Therapeutics
JF - American Journal of Therapeutics
SN - 1075-2765
IS - 5
ER -